Osimertinib Recruiting Phase 3 Trials for Non Small Cell Lung Cancer (Stage III) Treatment

IndicationsStatusPurposePhase
RecruitingTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT03521154A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)